Review argues GLP-1 eye risk is not a class effect

A review paper accepted September 10 in the journal Frontiers in Medicine argues that eye-related safety concerns linked to GLP-1 receptor agonist drugs are not a uniform "class effect" shared equally by every drug in the category ^[1]. Instead, the authors propose that differences in how each drug is built and how long it stays active in the body may explain why some GLP-1 drugs show stronger ties to eye problems than others ^[1].

The review focuses on two eye conditions: non-arteritic anterior ischemic optic neuropathy, or NAION, a form of vision loss caused by reduced blood flow to the optic nerve, and diabetic retinopathy, a diabetes-related eye disease that can worsen when blood sugar drops quickly ^[1]. The authors write that semaglutide, a longer-acting drug, has been "repeatedly linked" to increased risk of NAION and to early worsening of diabetic retinopathy in situations where blood sugar is corrected rapidly ^[1]. Semaglutide is sold under the brand names Ozempic, Wegovy, and Rybelsus.

By contrast, the review states that shorter-acting drugs such as liraglutide and exenatide show "much weaker" signals for these eye problems ^[1]. The authors say this difference may come down to how long a drug's active ingredient engages with GLP-1 receptors in the body and how quickly it brings blood sugar levels down, rather than a shared mechanism across every drug of this type ^[1]. The paper also floats a newer idea: that GLP-1 drugs might change pressure inside the skull in ways that affect blood flow to the eye, though the authors describe this as one of several possible explanations still being explored, alongside receptor-level differences in how drugs attach to and move through cells ^[1].

Importantly, this is a narrative review, meaning the authors gathered and interpreted existing research and ideas rather than running a new clinical study or collecting new patient data ^[1]. The paper does not report new trial results, new patient counts, or new statistics on how many people were affected. It is a scientific argument built from existing evidence, aimed at researchers, and the authors describe their model as making "testable predictions" that would need further study to confirm ^[1].

Why it matters for patients

For people taking or considering a GLP-1 drug, this review does not change what regulators have said about these medicines, and it is not a substitute for information from a doctor or pharmacist. What it does is offer a possible explanation for why concerns about NAION and retinopathy have centered more on semaglutide products like Ozempic and Wegovy than on older, shorter-acting GLP-1 drugs ^[1]. The authors note this could eventually matter for drug choice and for how closely doctors watch patients' eyes on certain drugs, but they frame this as a direction for future research rather than a settled conclusion ^[1].

The review also flags an unresolved question: how this risk balance applies to people who are not diabetic but take these drugs for weight loss, since much of the existing eye-safety data comes from diabetes research ^[1]. The authors list this as a key area still needing study ^[1]. The sources provided do not include newer drugs like tirzepatide, sold as Mounjaro or Zepbound, or orforglipron, sold as Foundayo, so it is not yet known how this framework would apply to those medicines.

What happens next

The paper was accepted September 10, 2026, with a final formatted version expected to publish soon afterward ^[1]. The authors call for head-to-head studies comparing how different GLP-1 drugs act on specific eye cell types, and for more research into the risk-benefit picture for people using these drugs for weight loss rather than diabetes ^[1]. No new clinical trials or regulatory actions tied to this review are described in the source material.